Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT04579367
Recruiting
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic acid and/or its fixed-dose combination with ezetimibe in managing plasma levels of low-density lipoprotein cholesterol (LDL-C). Secondary objectives are to document and evaluate as applicable: * Assessment of the cardiovascular risk of patients treated with bempedoic aci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Dr. Armin Öhlinger Kardiologe & innere Medizin, Dornbirn, Not set +490 locations
Conditions: Hypercholesterolemia, Mixed Dyslipidemia
Register for Updates
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
NCT02998567
Recruiting
HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours. The investigators will be investigating the safety and toxicity of the combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Royal Marsden Hospital, Sutton, Surrey +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396
Recruiting
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: City of Hope - Phoenix ( Site 0006), Goodyear, Arizona +36 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373
Recruiting
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/12/2025
Locations: University of Florida, Gainesville, Florida +25 locations
Conditions: Neuroblastoma
Register for Updates
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already bei... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: Tucson Clinical Research Institute, LLC, Tucson, Arizona +143 locations
Conditions: Lupus Erythematosus, Systemic
Register for Updates
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689
Recruiting
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +78 locations
Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Register for Updates
Virtual Reality in Elective Caesarean Births Study (VREC)
NCT07130084
Recruiting
This study will establish the safety of a known intervention in a novel setting. It will assess how maternal anxiety during the peri-operative period of an elective cesarean section (eCS) is affected by the introduction of a virtual reality (VR) tool. A cesarean section is the most common operation performed in the world. Indeed, locally, we perform approximately 450 eCS annually, equating to 10% of all births. High maternal anxiety in the peri-operative period is well recognised. Although anxie... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Bath Birthing Centre, Royal United Hospital Bath Foundation Trust, Bath, Not set
Conditions: Anxiety, Pregnancy, Pain
Register for Updates
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/12/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +76 locations
Conditions: Ulcerative Colitis
Register for Updates
Clinical Evaluation of a Paediatric Sleep Diagnosis Technology
NCT04031950
Recruiting
The objective of this project is to gather research data and subsequently evaluate algorithms to demonstrate clinical efficacy of a novel sleep apnoea detection system in the paediatric population. The Study will involve patients who will have been referred for diagnosis of sleep apnoea, and the ultimate aim will be to compare the output of a novel apnoea detection system against in -clinic polysomnography.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
08/12/2025
Locations: Sheffield Children Hospital, Sheffield, Not set +1 locations
Conditions: Sleep Apnea
Register for Updates
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/12/2025
Locations: Research Site, Tucson, Arizona +279 locations
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT05203172
Recruiting
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +62 locations
Conditions: Solid Tumors
Register for Updates
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702
Recruiting
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years. Study details for each participant include: The study duration... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
08/12/2025
Locations: Investigational Site Number: 8400007, Birmingham, Alabama +57 locations
Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Register for Updates